Literature DB >> 31679947

Entering the era of highly effective CFTR modulator therapy.

Edith T Zemanick1, Frank J Accurso2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31679947     DOI： 10.1016/S0140-6736(19)32676-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Pulmonary gene delivery-Realities and possibilities.

Authors:  Uday K Baliga; David A Dean
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-12

2.  Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions.

Authors:  Laura K Fawcett; Claire E Wakefield; Sheila Sivam; Peter G Middleton; Peter Wark; John Widger; Adam Jaffe; Shafagh A Waters
Journal:  ERJ Open Res       Date:  2021-01-18

3.  Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF).

Authors:  Helge Hebestreit; Susi Kriemler; Christian Schindler; Lothar Stein; Chantal Karila; Don S Urquhart; David M Orenstein; Larry C Lands; Jonathan Schaeff; Ernst Eber; Thomas Radtke
Journal:  Am J Respir Crit Care Med       Date:  2022-02-01       Impact factor: 21.405

Review 4.  Phase separation as a therapeutic target in tight junction-associated human diseases.

Authors:  Shuang Sun; Jun Zhou
Journal:  Acta Pharmacol Sin       Date:  2020-07-21       Impact factor: 6.150
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.